XRCC1

Implication of polymorphisms in DNA repair genes with an increased risk of hepatocellular carcinoma

J. S. Wu, Chen, Y. P., Wang, L. C., Yang, Y. J., Deng, C. W., Hou, B. X., He, Z. L., and Chen, J. X., Implication of polymorphisms in DNA repair genes with an increased risk of hepatocellular carcinoma, vol. 13, pp. 3812-3818, 2014.

We explored the association between 4 XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms with the development and prognosis of hepatocellular carcinoma (HCC). A total of 218 cases with HCC and 277 healthy controls were included in the study. Genotyping of the XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms was performed in a 384-well plate format on the Sequenom MassARRAY platform.

Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer

Z. Y. Jin, Zhao, X. T., Zhang, L. N., Wang, Y., Yue, W. T., and Xu, S. F., Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer, vol. 13, pp. 7617-7625, 2014.

This study aimed to investigate the effects of single-nucleotide polymorphisms (SNPs) XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XRCC3 Thr241Met, XPG His104Asp, and XPG His46His in genes involved in the DNA-repair pathway on the outcomes of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). The study period was from January 2005 to January 2006, and 378 NSCLC patients were enrolled within 1 month after being diagnosed with NSCLC. Genomic DNA was extracted using the Qiagen Blood Kit.

Subscribe to XRCC1